J. Jiao

发表

Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin

A. Bernard, N. Vaccaro, M. Acharya, 2015, Clinical pharmacology in drug development.

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

A. Tolcher, R. Pili, K. Chi, 2012, Cancer Chemotherapy and Pharmacology.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, L. D. De Zwart, J. Snoeys, 2018, Leukemia & lymphoma.

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer

F. Saad, R. de Wit, W. Edenfield, 2018, Cancer Chemotherapy and Pharmacology.

Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

D. Ouellet, J. Jiao, J. de Jong, 2020, Pharmacology research & perspectives.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

J. Carles, I. Durán, J. Jiao, 2020, Clinical Pharmacokinetics.

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study

D. Ouellet, I. Poggesi, M. De Meulder, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men

R. Vries, A. Bernard, M. Acharya, 2012, Cancer Chemotherapy and Pharmacology.

Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.

G. Hammer, R. Auchus, J. Jiao, 2014, The Journal of clinical endocrinology and metabolism.

Peginterferon alfa‐2a for hepatitis C after liver transplantation: Two randomized, controlled trials

N. Chalasani, P. Ferenci, W. Vogel, 2005, Hepatology.

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

C. Kollmannsberger, K. Chi, T. Griffin, 2015, Journal of clinical pharmacology.

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. de Jong, 2017, Cancer Chemotherapy and Pharmacology.

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

J. Snoeys, A. Bernard, J. Jiao, 2016, Drug Metabolism and Disposition.

IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES TO ASSESS THE EFFECT OF ABIRATERONE ACETATE , ABIRATERONE , AND METABOLITES OF ABIRATERONE ON CYP 2 C 8 ACTIVITYa

J. Snoeys, A. Bernard, J. Jiao, 2016 .

Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment

T. Marbury, C. Haqq, E. Lawitz, 2014, Journal of clinical pharmacology.

Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing

A. Bernard, N. Vaccaro, J. Jiao, 2014, Cancer Chemotherapy and Pharmacology.

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

Juthamas Sukbuntherng, Jan Snoeys, L. D. De Zwart, 2016, British journal of clinical pharmacology.

The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure

D. Ouellet, J. Jiao, J. Sukbuntherng, 2018, Cancer Chemotherapy and Pharmacology.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

William Smith, T. Marbury, E. Lawitz, 2017, Leukemia & lymphoma.

7057 POSTER A Phase 1 Single Dose Open-label Reduced/staged Pharmacokinetic (PK) and Safety Study of Abiraterone Acetate (AA) in Men With Impaired Renal Function

T. Marbury, C. Haqq, M. Acharya, 2011 .

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

A. Tolcher, B. Kaiser, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

D. Ouellet, J. Jiao, J. Sukbuntherng, 2017, Cancer Chemotherapy and Pharmacology.

Peginterferon Alfa-2 a for Hepatitis C After Liver Transplantation : Two Randomized , Controlled Trials

R. Fontana, N. Chalasani, P. Ferenci, 2005 .

The possible relationship between dopamine transporters and abuse relapse after heroin abstinence: a brain SPECT data analysis

J. Jiao, Pu-Jiao Song, Fan Yuan, 2006 .

Does peginterferon ALFA-2A have an impact on hepatitis C recurrence after orthotopic liver transplantation?

Z. Younossi, P. Ferenci, W. Vogel, 2005 .

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

J. Snoeys, J. Jiao, J. Monbaliu, 2016, Drug Metabolism and Disposition.

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

D. Ouellet, J. Snoeys, J. Jiao, 2018, Leukemia & lymphoma.

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

J. Jiao, P. Hellemans, N. Haddish-Berhane, 2024, Clinical pharmacokinetics.